Uriach reinforces its commitment within the natural and self-care products health segment and consolidates its business model in Europe. After a decade marked by a dozen acquisitions across the Old Continent, the Catalan pharmaceutical company closed the year 2025 with a 3% increase in sales, approaching the 500 million euros it had set as a goal when it launched its strategic plan in 2015. Although the improvement falls short of the figures recorded the previous year –revenue in 2024 increased by 54%–, the company acknowledges that the past year has been characterized by a "complex" context after several years of high-growth markets.

The Catalan pharmaceutical company Uriach will exceed the revenue projections included in its 2020-2025 strategic plan, which called for reaching €500 million this year. The family-owned company achieved revenue of €476 million last year, a 54% increase over the previous year, thanks to acquisitions made in Europe to lead the self-consumption pharmaceutical business based on natural ingredients.